Impact of HFE genetic testing on clinical presentation of hereditary hemochromatosis: New epidemiological data

BMC Medical Genetics

Volumn 6, Issue , 2005, Pages

  Scotet, Virginie ^a   Le Gac, Gerald ^b   Merour, Marie Christine ^b   Mercier, Anne Yvonne ^b   Chanu, Brigitte ^b   Ka, Chandran ^b,c   Mura, Catherine ^c   Nousbaum, Jean Baptiste ^d   Ferec, Claude ^a,b  

^a INSERM   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FERRITIN; HFE PROTEIN; IRON; CYSTEINE; HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; TYROSINE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; FRANCE; GENETIC ANALYSIS; HEMOCHROMATOSIS; HEPATOMEGALY; HOMOZYGOSITY; HUMAN; IRON BLOOD LEVEL; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PHLEBOTOMY; SEX RATIO; SKIN PIGMENTATION; STATISTICAL ANALYSIS; AMINO ACID SUBSTITUTION; GENETIC SCREENING; GENETICS; GENOTYPE; METHODOLOGY; MIDDLE AGED; MOLECULAR DIAGNOSIS; MOLECULAR EPIDEMIOLOGY;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; COHORT STUDIES; CYSTEINE; FEMALE; FRANCE; GENETIC TESTING; GENOTYPE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR EPIDEMIOLOGY; SEX RATIO; TYROSINE;

EID: 26444490676     PISSN: 14712350     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-6-24     Document Type: Article

References (49)

1. Bomford A: Genetics of haemochromatosis. Lancet 2002, 360:1673-1681.
2. Nicolas G, Viatte L, Lou DQ, Bennoun M, Beaumont C, Kahn A, Andrews NC, Vaulont S: Constitutive hecidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003, 34:97-101.
3. Muckenthaler M, Roy CN, Custodio AO, Minana B, deGraaf J, Montross LK, Andrews NC, Hentze MW: Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet 2003, 34:102-107.
4. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramaniam VN, Powell LW, Anderson GJ, Ramm GA: Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 2003, 361:669-673.
5. Camaschella C, Roetto A, Cali A, De Gobbi M, Garozzo G, Carella M, Majorano N, Totaro A, Gasparini P: The gene TfR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000, 25:14-15.
6. Roetto A, Daraio F, Alberti F, Porporato P, Cali A, De Gobbi M, Camaschella C: Hemochromatosis due to mutations in transferrin receptor 2. Blood Cells Mol Dis 2002, 29:465-470.
7. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, Cali A, De Gobbi M, Gasparini P, Camaschella C: New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001, 97:2555-2560.
8. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, Snijders PJ, Rutten WP, Sandkuijl LA, Oostra BA, van Duijn CM, Heutink P: A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001, 28:213-214.
9. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A: Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001, 108:619-623.
10. Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, Kobune M, Takada K, Takimoto R, Hamada H, Ikeda T, Niitsu Y: A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001, 69:191-197.
11. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson J, Risler JK, Zaborowska C, Babakaiff R, Radomski CC, Pape TD, Davidas O, Christakis J, Brissot P, Lockitch G, Ganz T, Hayden MR, Goldberg YP: Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004, 36:77-82.
12. Bradley LA, Haddow JE, Palomaki GE: Population screening for haemochromatosis: a unifying analysis of published intervention trials. J Med Screen 1996, 3:178-184.
13. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP: Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988, 318:1355-1362.
14. McDonnell SM, Phatak PD, Felitti V, Hover A, McLaren GD: Screening for hemochromatosis in primary care settings. Ann Intern Med 1998, 129:962-970.
15. Niederau C, Niederau CM, Lange S, Littauer A, Abdel-Jalil N, Maurer M, Haussinger D, Strohmeyer G: Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998, 128:337-345.
16. Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O'Leary MT, Braggins C, Cappuccio JD: Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med 1998, 129:954-961.
17. Niederau C, Strohmeyer G, Stremmel W: Epidemiology, clinical spectrum and prognosis of hemochromatosis. Adv Exp Med Biol 1994, 356:293-302.
18. Powell LW, George DK, McDonnell SM, Kowdley KV: Diagnosis of hemochromatosis. Ann Intern Med 1998, 129:925-931.
19. Piperno A: Classification and diagnosis of iron overload. Hematologica 1998, 83:447-455.
20. Lyon E, Frank EL: Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem 2001, 47:1147-1156.
21. Hanson EH, Imperatore G, Burke W: HFE gene and hereditary hemochromatosis: a HuGE review Am J Epidemiol 2001, 154:193-206.
22. McCullen MA, Crawford DH, Hickman PE: Screening for hemochromatosis. Clin Chim Acta 2002, 315:169-186.
23. Moirand R, Adams PC, Bicheler V, Brissot P, Deugnier Y: Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med 1997, 127:105-110.
24. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R, Jr., Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996, 13:399-408.
25. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, Morikang E, Prass CE, Starnes SM, Wolff RK, Parkkila S, Sly WS, Schatzman RC: The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997, 272:14025-14028.
26. Waheed A, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, Feder JN, Schatzman RC, Britton RS, Bacon BR, Sly WS: Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 1997, 94:12384-12389.
27. Burke W, Thomson E, Khoury MJ, McDonnell SM, Press N, Adams PC, Barton JC, Beutler E, Brittenham G, Buchanan A, Clayton EW, Cogswell ME, Meslin EM, Motulsky AG, Powell LW, Sigal E, Wilfond BS, Collins FS: Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998, 280:172-178.
28. Barton JC, Sawada-Hirai R, Rothenberg BE, Acton RT: Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cells Mol Dis 1997, 25:147-155.
29. Mura C, Raguenes O, Ferec C: HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999, 93:2502-2505.
30. Trent RJ, Le H, Yu B, Young G, Bowden DK: DNA testing for haemochromatosis: diagnostic, predictive and screening implications. Pathology 2000, 32:274-279.
31. Press RD: Hereditary hemochromatosis: impact of molecular and iron-based testing on the diagnosis, treatment, and prevention of a common, chronic disease. Arch Pathol Lab Med 1999, 123:1053-1059.
32. Mura C, Nousbaum JB, Verger P, Moalic MT, Raguenes O, Mercier AY, Ferec C: Phenotype-genotype correlation in haemochromatosis subjects. Hum Genet 1997, 101:271-276.
33. Scotet V, Merour MC, Mercier AY, Chanu B, Le Faou T, Raguenes O, Le Gac G, Mura C, Nousbaum JB, Ferec C: Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol 2003, 158:129-134.
34. Le Gac G, Mura C, Ferec C: Complete scanning of the hereditary hemochromatosis gene (HFE) by use of denaturing HPLC. Clin Chem 2001, 47:1633-1640.
35. Simon M, Le Mignon L, Fauchet R, Yaouanq J, David V, Edan G, Bourel M: A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association. Am J Hum Genet 1987, 41:89-105.
36. Adams PC, Kertesz AE, Valberg LS: Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991, 90:445-449.
37. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G: Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996, 110:1107-1119.
38. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C: HAMP as a modifier gene that increases the phenotypic expression of the HFE p.C282Y homozygous genotype. Blood 2004, 103:2835-2840.
39. Le Gac G, Scotet V, Ka C, Gourlaouen I, Bryckaert L, Jacolot S, Mura C, Ferec C: The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004, 13:1913-1918.
40. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T: Penetrance of 845G>A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002, 359:211-218.
41. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW: A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999, 341:718-724.
42. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, Kushner JP: Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000, 343:1529-1535.
43. McCune A, Worwood M: Penetrance in hereditary hemochromatosis. Blood 2003, 102:2696-2697.
44. Waalen J, Nordestgaard BG, Beutler E: The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 2005, 18:203-220.
45. McCune CA, Al Jader LN, May A, Hayes SL, Jackson HA, Worwood M: Hereditary haemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002, 111:538-543.
46. Adams P, Brissot P, Powell LW: EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000, 33:485-504.
47. Njajou OT, Alizadeh BZ, van Duijn CM: Is genetic screening for hemochromatosis worthwhile? Eur J Epidemiol 2004, 19:101-108.
48. Milman N, Pedersen P, Steig T, Byg KE, Graudal N, Fenger K: Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients. Ann Hematol 2001, 80:737-744.
49. Guttmacher AE, Collins FS: Genomic medicine--a primer. N Engl J Med 2002, 347:1512-1520.